

UCSF

UC San Francisco Previously Published Works

Title

Serotonin Regulates Adult β -Cell Mass by Stimulating Perinatal β -Cell Proliferation.

Permalink

<https://escholarship.org/uc/item/05w2b5mh>

Journal

Diabetes, 69(2)

ISSN

0012-1797

Authors

Moon, Joon Ho
Kim, Yeong Gi
Kim, Kyuho
et al.

Publication Date

2020-02-01

DOI

10.2337/db19-0546

Peer reviewed



Serotonin Regulates Adult β -Cell Mass by Stimulating Perinatal β -Cell Proliferation

Joon Ho Moon,¹ Yeong Gi Kim,¹ Kyuho Kim,¹ Sho Osonoi,² Shuang Wang,³ Diane C. Saunders,⁴ Juehu Wang,⁵ Katherine Yang,⁵ Hyeongseok Kim,^{1,6} Junguee Lee,⁷ Ji-Seon Jeong,⁸ Ronadip R. Banerjee,⁹ Seung K. Kim,¹⁰ Yingjie Wu,^{3,11} Hiroki Mizukami,² Alvin C. Powers,^{4,12} Michael S. German,^{5,13} and Hail Kim^{1,14}

Diabetes 2020;69:205–214 | <https://doi.org/10.2337/db19-0546>

A sufficient β -cell mass is crucial for preventing diabetes, and perinatal β -cell proliferation is important in determining the adult β -cell mass. However, it is not yet known how perinatal β -cell proliferation is regulated. Here, we report that serotonin regulates β -cell proliferation through serotonin receptor 2B (HTR2B) in an autocrine/paracrine manner during the perinatal period. In β -cell-specific *Tph1* knockout (*Tph1* β KO) mice, perinatal β -cell proliferation was reduced along with the loss of serotonin production in β -cells. Adult *Tph1* β KO mice exhibited glucose intolerance with decreased β -cell mass. Disruption of *Htr2b* in β -cells also resulted in decreased perinatal β -cell proliferation and glucose intolerance in adulthood. Growth hormone (GH) was found to induce serotonin production in β -cells through activation of STAT5 during the perinatal period. Thus, our results indicate that GH-GH receptor-STAT5-serotonin-HTR2B signaling plays a critical role in determining the β -cell mass by regulating perinatal β -cell proliferation, and

defects in this pathway affect metabolic phenotypes in adults.

Diabetes develops when β -cells fail to meet insulin demand; a sufficient β -cell mass is crucial for preventing diabetes, and people with decreased β -cell mass have increased susceptibility to type 2 diabetes (1,2). Despite the importance of the adult β -cell mass, it is not yet clear how a proper amount of β -cell mass is achieved.

During fetal development, insulin-producing β -cells differentiate from endocrine progenitor cells, and the newly developed β -cells actively proliferate during the perinatal period to achieve the adult β -cell mass (3). After the perinatal period, β -cells maintain a low proliferation rate unless sustained metabolic stress increases systemic insulin demand. Therefore, perinatal β -cell proliferation is important in determining the adult β -cell mass and susceptibility to type 2 diabetes. However, we know little

¹Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea

²Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

³Institute of Genome Engineered Animal Models for Human Disease and National Center of Genetically Engineered Animal Models for International Research, Dalian Medical University, Dalian, Liaoning, China

⁴Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

⁵Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Diabetes Center and Hormone Research Institute, University of California, San Francisco, San Francisco, CA

⁶Department of Biochemistry, Chungnam National University School of Medicine, Daejeon, Korea

⁷Department of Pathology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea

⁸Center for Bioanalysis, Division of Chemical and Medical Metrology, Korea Research Institute of Standards and Science, Daejeon, Korea

⁹Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama School of Medicine, Birmingham, AL

¹⁰Department of Developmental Biology, Stanford University School of Medicine, Palo Alto, CA

¹¹Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn Mount Sinai School of Medicine, New York, NY

¹²VA Tennessee Valley Healthcare System, Nashville, TN

¹³Department of Medicine, University of California, San Francisco, San Francisco, CA

¹⁴KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Daejeon, Korea

Corresponding authors: Hail Kim, hailkim@kaist.edu, and Michael S. German, mgerman@ucsf.edu

Received 1 June 2019 and accepted 14 November 2019

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db19-0546/-/DC1>.

J.H.M. and Y.G.K. contributed equally to this work.

© 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

about how β -cell proliferation is physiologically regulated during the perinatal period.

Serotonin (5-hydroxytryptamine [5-HT]) is a neurotransmitter that is synthesized from tryptophan by the sequential actions of tryptophan hydroxylase (TPH) and aromatic amino acid decarboxylase. 5-HT exerts its biological action by binding to 5-HT receptor (HTR) (4,5). Two isoforms of TPH are expressed in a mutually exclusive manner: TPH1 in peripheral nonneuronal tissues and TPH2 in neurons of the central and enteric nervous systems (4,5). In pancreatic β -cells, TPH1 expression and 5-HT production are simultaneously increased during pregnancy. 5-HT released from β -cells acts locally to increase β -cell proliferation and insulin secretion through HTR2B and HTR3, respectively (6,7). Intriguingly, 5-HT production in β -cells also increases robustly during the perinatal period (6,8). These data prompted us to explore the physiological role of 5-HT in perinatal β -cell expansion.

Here, we show that 5-HT regulates the adult β -cell mass by stimulating perinatal β -cell proliferation through HTR2B in an autocrine/paracrine manner. Growth hormone (GH), but not prolactin (PRL), induces 5-HT production in β -cells during the perinatal period. Human β -cells also produce 5-HT during the perinatal period, suggesting that 5-HT may contribute to determining the human β -cell mass and susceptibility to diabetes.

RESEARCH DESIGN AND METHODS

Animal Experiments

All mice used in this study were C57BL/6J background strain. Mice were housed in a specific-pathogen-free facility at the Korea Advanced Institute of Science and Technology, with 12-h light and dark cycles under isothermal and isohumid conditions. Normal chow diet (SCD, D10001; Research Diets) and water were given ad libitum. To generate β -cell-specific knockout (β KO) mice of *Tph1*, *Htr2b*, *Prlr*, and *Stat5*, *Ins2-Cre* (MGI 2387657) mice were mated with mice harboring a *Tph1* floxed allele (MGI 6271993), an *Htr2b* floxed allele (MGI 3837400), a *Prlr* floxed allele, and a *Stat5* floxed allele (MGI 3055318), respectively (9–14). To generate *Ghr* β KO mice, *Ins2-Cre* mice were mated with mice harboring a *Ghr* floxed allele (MGI 5056123) (15,16). All Cre mice used in this study lacked the GH minigene, which has been shown to induce ectopic 5-HT production (17,18). *Htr1b*^{tm1.1(KOMP)VIcg} (MGI 5463939) and *Htr1d*^{tm1.1(KOMP)VIcg} (MGI 5529062) mice were purchased from KOMP. For experiments involving adult mice, 9-week-old male mice were used. For high-fat diet (HFD) studies, the diet (60% kcal fat, D12492; Research Diets) was fed to 12-week-old male mice for 8 weeks. For the S-961 (insulin receptor antagonist; Novo Nordisk) study, 100 nmol/kg mouse was given twice a day intraperitoneally for 7 days. Given that glucose levels are comparable in Cre mice and floxed control mice, Cre

littermates of the experimental (KO) mice were used as the control, unless otherwise stated.

Human Pancreatic Tissues

Human pancreas autopsy specimens were obtained from the archives of the Department of Pathology and Molecular Medicine, Hirosaki University. All specimens were formalin-fixed and paraffin-embedded for further staining. Conventional hematoxylin and eosin (H&E) staining was performed in all cases. Fetal cases were from a stillborn baby with no apparent malformations on the outer surface. An 8-day-old sample was obtained from a male newborn baby whose cause of death was cardiopulmonary insufficiency secondary to osteogenesis imperfecta. A 3-month-old sample was obtained from a female infant whose cause of death was sudden infant death syndrome. Pancreas samples from a 35-year-old pregnant woman (gestational age 37 weeks; cause of death, pulmonary embolism) and a 72-year-old man (cause of death, myocardial infarction) were used as controls. The use of paraffin blocks and the study design were approved by the ethics committee of the Hirosaki University School of Medicine (approval number #2014-269), and the study conformed to the provisions of the Declaration of Helsinki.

Immunostaining and β -Cell Area Measurements

Mouse pancreas tissues were harvested and fixed in 10% neutral-buffered formalin solution (Sigma-Aldrich) for 2 h (perinatal) or 4 h (adult) at room temperature and washed with deionized water for 30 min. After washing, the tissues were processed with an automatic tissue processor (TP1020; Leica Biosystems) and embedded in molten paraffin wax. Paraffin-embedded tissues were sliced at 4- μ m thickness and mounted on adhesive glass slides (081000; Paul Marienfeld). Sections were manually deparaffinized in xylene and rehydrated in ethanol for further staining. Antigen retrieval was performed by incubating the slides in sodium citrate buffer (10 mmol/L sodium citrate, pH 6.0) with a pressure cooker for 15 min. For immunofluorescent staining, samples were blocked with 2% donkey serum in PBS for 1 h at room temperature. Slides treated with the following primary antibodies were incubated at 4°C overnight: anti-5-HT antibody (rabbit, dilution factor 1:1,000; ImmunoStar), anti-glucagon antibody (1:1,000, mouse; Sigma), anti-insulin antibody (1:1,000, guinea pig; Dako), anti-Nkx6.1 antibody (1:100, mouse; Developmental Studies Hybridoma Bank), anti-Pdx1 antibody (1:100, mouse; Developmental Studies Hybridoma Bank), anti-Ki-67 (1:1,000, rabbit; Abcam), and anti-phospho-Histone H3 antibody (1:1,000, rabbit; Millipore). After incubation and washing, the following secondary antibodies were treated and incubated for 2 h at room temperature: Alexa 594-conjugated donkey anti-mouse IgG (1:1,000; Jackson ImmunoResearch), Alexa 647-conjugated donkey anti-rabbit IgG (1:1,000; Jackson ImmunoResearch), and FITC-conjugated donkey anti-guinea pig IgG (1:1,000; Jackson ImmunoResearch). In

Situ Cell Death Detection Kit, Fluorescein (TUNEL; Sigma-Aldrich) was used to measure apoptosis. Samples were treated with DAPI (1:2,000; Invitrogen) for 5 min and mounted with fluorescence mounting medium (Dako). Pictures were obtained using a confocal microscope (LSM 780; Carl Zeiss) or a fluorescence microscope with a DS-Ri2 camera (Nikon). Immunofluorescence intensity was measured with region-of-interest statistics calculated using Nikon NIS-Elements version 4.3 software (reference range 0–256). 5-HT immunofluorescence intensity was measured in β -cells positive for immunofluorescence staining of insulin. The background intensity was measured in exocrine pancreas to evaluate whether the obtained images were suitable for comparison.

Immunohistochemistry was conducted with a biotin-free polymer detection system for 5-HT (MACH 3; Biocare Medical). After the application of secondary antibody for rabbit IgG, the immunoreaction products were colorized with diaminobenzidine (Thermo Fisher Scientific). Specificity was confirmed by the lack of positive staining after omission of the first antibody or replacement with non-immune serum. The sections were observed and captured by bright-field microscopy (Axio Imager A1 or M1; Carl Zeiss).

For the β -cell mass and proliferation measurements, slides of fresh-frozen paraffin-embedded pancreas were chosen with an 80- μ m interval. These slides were immunostained with insulin, and whole slides were scanned with JuLI Stage (NanoEntek). β -Cell mass was measured by insulin immunoreactive area divided by whole-pancreas area (more than eight slides per mouse). β -Cell proliferation was measured by the percentage of insulin and phospho-Histone H3 copositive cells in all β -cells (>2,000 β -cells per mouse).

Glucose Dynamics

For intraperitoneal glucose tolerance test and in vivo glucose-stimulated insulin secretion (GSIS) test, mice were fasted for 16 h, and D-glucose (2 g/kg body weight) was injected intraperitoneally. Blood glucose level was measured from tail vein using a glucometer (GlucoDr.Plus; Allmedicus). For insulin measurement, blood was collected at 0, 15, and 30 min after glucose injection in a heparinized tube, which was immediately centrifuged in 1,500g for 10 min at 4°C. Plasma insulin concentration was measured using an ultrasensitive insulin ELISA kit (80-INSMSU-E01; ALPCO). For insulin tolerance test, mice were fasted for 6 h before an intraperitoneal Humulin R (Eli Lilly) injection (0.75 units/kg body weight).

For ex vivo GSIS, mouse islets were isolated using collagenase. The major process of the technique was described previously (19). First, islets were incubated at 37°C in humidified gas of 5% CO₂ and 95% air in RPMI medium (Thermo Fisher Scientific) with 100 units/mL penicillin-streptomycin (Thermo Fisher Scientific) and 10% FBS (Thermo Fisher Scientific). After 4 h of incubation, islets were moved to Krebs-Ringer HEPES (KRH) buffer (pH 7.4, 115 mmol/L NaCl, 25 mmol/L HEPES, 24 mmol/L NaHCO₃, 5 mmol/L KCl, 1 mmol/L MgCl₂, 2.5 mmol/L

CaCl₂, and 1 mg/mL BSA) containing 2.8 mmol/L glucose for 30 min. Islets were handpicked ($n = 10$ size-matched islets per individual sample) to a 12-well noncoated dish. To measure basal insulin secretion, samples were incubated with 2.8 mmol/L glucose containing KRH buffer for 15 min, and 50 μ L of supernatants were obtained for insulin measurements. For high-glucose stimulation, samples were incubated with 16.8 mmol/L glucose containing KRH buffer for 15 min, and supernatants were obtained. Next, the islets were sonicated and incubated in acid-ethanol (1.5% HCl in 100 mL of 70% ethanol) for 18 h at 4°C for intracellular insulin extraction. The same volume of 1 mol/L Tris Cl buffer (pH 8.0) was added for neutralization. All supernatants were immediately snap frozen with liquid nitrogen and kept frozen at -80°C until ELISA experiments. Insulin secretion was calculated by dividing the secreted insulin by the total insulin content extracted from the islets.

GH Studies and 5-HT Measurements

For experiments with GH, islets were isolated from mice at 3 to 4 weeks of age and incubated in RPMI medium. β TC3 and MIN6 cells were maintained in DMEM containing 25 mmol/L glucose and supplemented with 10% or 15% FBS, 100 units/mL penicillin, 0.1 mg/mL streptomycin, and, where applicable (i.e., for MIN6 cells), 71.5 μ mol/L 2-mercaptoethanol. Cells were incubated at 37°C in a humidified incubator containing 5% CO₂. For GH treatment, cells were incubated in serum-free medium for 12 h, and then recombinant mouse GH (National Hormone and Peptide Program) was added to the medium. RNA was extracted 24 h after the treatment.

For measurement of 5-HT secretion, neonatal pancreas was harvested at postnatal day 0 (P0) and washed with PBS. The P0 pancreas was incubated in 1 mL of KRH buffer supplemented with protease inhibitor cocktail for 10 min in a CO₂ incubator. Supernatants were obtained, and the secreted 5-HT concentration was measured using ELISA (LDN, Nordhorn, Germany). This value was normalized to the protein content, which was measured using the bicinchoninic acid technique (Thermo Fisher Scientific).

Quantitative RT-PCR

Total RNA was extracted using TRIzol (Invitrogen) following the manufacturer's protocol. One microgram of total RNA was used to generate cDNA High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR (qRT-PCR) was performed with Fast SYBR Green Master Mix (Applied Biosystems) using a Viia 7 Real-Time PCR System (Applied Biosystems). Gene expression was calculated by relative gene expression analysis using the Δ Ct (threshold cycle) method. *Actb* was used as an internal control. Primer sequences are listed in Supplementary Table 1.

Statistical Analysis

All data are presented as the mean \pm SEM. Statistical significance was obtained by Student *t* test (two-tailed) or




Figure 1—5-HT regulates β -cell proliferation during the perinatal period. **A:** Immunohistochemical staining (5-HT in brown) and H&E staining in perinatal human pancreata. Fetal (gestational age 24 weeks), postnatal 8-day-old, and 3-month-old pancreata were stained. Pancreas samples from a 35-year-old pregnant woman (gestational age 37 weeks) and a 72-year-old man were used as a positive and negative control, respectively. **B:** Immunofluorescent (IF) staining of perinatal pancreas from C57BL/6J mice labeled insulin (green) and 5-HT (red). **C–F:** Pancreata of control (Cre) and *Tph1* β KO mice were assessed at P0. **C:** Representative IF staining labeled insulin (green) and amylose (AMYL) (red) at P0. Images of a whole-slide section were obtained using a slide scanner. **D:** β -Cell mass was quantified as the percentage of insulin-positive area over whole pancreas area at P0 ($n = 4$ mice/group). **E:** IF staining labeled insulin (green) and phospho-Histone H3 (PHH3) (red). Arrows indicate insulin and PHH3 cospicuous cells. β -Cell proliferation was quantified by counting the percentage of insulin-positive cells labeled with PHH3 at P0 ($n = 4$ mice/group). **F:** mRNA levels of cyclin families were measured by qRT-PCR in RNAs extracted from pancreata at P0 ($n = 4$ –5 mice/group). Scale bars = 50 μ m. Data are mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. INS, insulin.

ANOVA to compare differences among three or more groups. Tukey honestly significant difference method was used for post hoc analysis. Statistical analyses were conducted using SPSS version 22 software (IBM Corporation). The levels of statistical significance were $P < 0.05$, $P < 0.01$, and $P < 0.001$.

Data and Resource Availability

All data that support the findings of this study are available from the authors upon reasonable request.

RESULTS

5-HT Production in β -Cells During the Perinatal Period

We detected the presence of 5-HT in human pancreatic islets during the perinatal period, ranging from a gestational age of 24 weeks to a postnatal age of 19 months (Fig.

1A and Supplementary Fig. 1A and B). 5-HT-positive cells were more frequently observed during the perinatal period, and 5-HT staining was confined to endocrine cells. Similarly, 5-HT staining was observed in mouse β -cells at P0–P5, and the expression pattern of the *Tph1* mRNA in pancreas paralleled the change in 5-HT immunostaining (Fig. 1B and Supplementary Fig. 1C–E). In humans, the mRNA expression of *TPH1* was higher than that of *TPH2* in β -cells, and *TPH1* mRNA expression was higher in fetal β -cells than in adult β -cells (20) (Supplementary Table 2). These data suggest that 5-HT may have a common function in human and rodent β -cells during the perinatal period and that 5-HT production mainly depends on *TPH1* than on *TPH2*.

To elucidate the physiological role of 5-HT in β -cells, we generated *Tph1* β KO mice (12). *Tph1* β KO was confirmed




Figure 2—5-HT regulates adult β -cell mass and is necessary to maintain glucose homeostasis. Metabolic phenotypes were evaluated in 9-week-old male control and *Tph1* β KO mice. **A** and **B**: Blood glucose and plasma insulin levels were measured after intraperitoneal glucose injection (2 g/kg) after a 16-h fast. Both Cre-only and floxed-only mice were used as controls for the glucose tolerance test. Because glucose levels were comparable between the two groups, Cre-only mice were used as the control in further experiments ($n = 4$ –8 mice/group). **C**: Secreted insulin was measured with ELISA after a 15-min incubation of islets isolated from 9-week-old control (Cre) and *Tph1* β KO mice in 2.8 or 16.8 mmol/L glucose. Insulin secretion was normalized to the total insulin content extracted from the islets ($n = 5$ /group). **D**: β -Cell mass was quantified as the percentage of insulin-positive area over whole-pancreas area of 9-week-old mice ($n = 4$ mice/group). **E**: Immunofluorescent staining labeled insulin (green) and Ki-67 (red), with arrows indicating insulin and Ki-67 copositive cells. β -Cell proliferation was quantified by counting the percentage of insulin-positive cells labeled with Ki-67 in 9-week-old mice ($n = 4$ mice/group). **F**: Pancreas weight was measured after harvest in 9-week-old mice ($n = 4$ mice/group). Scale bar = 50 μ m. Data are mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, control (Cre) vs. KO; ## $P < 0.01$, control (floxed) vs. KO. INS, insulin.

by decreased *Tph1* mRNA expression in the pancreas at P0 and the reduction of 5-HT production to a level undetectable by immunofluorescence staining in β -cells during the perinatal period and pregnancy (Supplementary Fig. 2A and B). Next, we evaluated 5-HT secretion from β -cells in the neonatal P0 pancreas (Supplementary Fig. 2C). Glucose did not stimulate 5-HT secretion in the P0 pancreas because β -cells were not mature enough to sense the increase in glucose levels. Tolbutamide treatment increased 5-HT secretion in the P0 pancreas, but this response was perturbed in the *Tph1* β KO pancreas. These results suggest that 5-HT is produced and secreted in the β -cell during the perinatal period and can activate HTR in an autocrine/paracrine manner.

5-HT Stimulates Perinatal β -Cell Proliferation

We further explored the physiological role of 5-HT in *Tph1* β KO mice. The loss of 5-HT production did not affect β -cell differentiation, as evidenced by normal expression of PDX1 and NKX6.1 (Supplementary Fig. 2D). Intriguingly, the β -cell mass was remarkably reduced in *Tph1* β KO mice, whereas the size of the pancreas was unchanged (Fig. 1C and D and Supplementary Fig. 2E). Immunofluorescence staining of proliferation markers (phospho-Histone

H3 and Ki-67) and TUNEL assays revealed that β -cell proliferation was reduced by $\sim 75\%$ in *Tph1* β KO mice without obvious induction of β -cell death (Fig. 1E and Supplementary Fig. 2F and G). The expression levels of cyclin family members (i.e., D1, D2, D3, A2, B1) were reduced in the pancreas of *Tph1* β KO mice at P0 (Fig. 1F). Collectively, these data suggest that 5-HT increases the β -cell mass by promoting perinatal β -cell proliferation.

To examine the long-term impacts of the reduced perinatal β -cell proliferation seen in *Tph1* β KO mice, we evaluated the metabolic phenotypes of *Tph1* β KO mice at 9 weeks of age. *Tph1* β KO mice showed normal growth and insulin sensitivity (Supplementary Fig. 3A and B); however, their glucose tolerance was impaired (Fig. 2A). Plasma insulin levels at fasting and 15 min after glucose administration were lower, and the insulin secretory capacity was lower in *Tph1* β KO islets than in control islets (Fig. 2B and C). In adult *Tph1* β KO mice, the β -cell proliferation and pancreas size were comparable to those of control mice, but the β -cell mass was reduced by more than half (to $\sim 40\%$) compared with that of control mice (Fig. 2D–F). To investigate the mechanism underlying the reduction in the β -cell mass of adult *Tph1* β KO mice, we evaluated




Figure 3—HTR2B is the downstream target of 5-HT in perinatal β -cells. *A*: mRNA expression levels of indicated HTRs were assessed by qRT-PCR in RNAs extracted from pancreata during embryonic development ($n = 4$ mice/group). *B–E*: Pancreata of control (Cre) and *Htr2b* β KO at P0 were evaluated. *B*: H&E staining was performed in control (Cre) and *Htr2b* β KO pancreata at P0. *C*: β -Cell mass was quantified as the percentage of insulin-positive area over whole-pancreas area at P0 ($n = 4$ mice/group). *D*: Pancreas weight was measured after harvest at P0 ($n = 4–5$ mice/group). *E*: Immunofluorescent staining labeled insulin (green) and phospho-Histone H3 (PHH3) (red), with arrows indicating insulin and PHH3 copositive cells. β -Cell proliferation was quantified by counting the percentage of insulin-positive cells labeled with PHH3 at P0 ($n = 4$ mice/group). *F–J*: Metabolic phenotypes were evaluated in 9-week-old male control and *Htr2b* β KO mice. *F* and *G*: Blood glucose and plasma insulin levels were measured after intraperitoneal glucose injection (2 g/kg) after a 16-h fast. Both Cre-only and floxed-only mice were used as controls for glucose tolerance tests. Because glucose levels were comparable between the two, Cre-only mice were used as the control in further experiments ($n = 4$ mice/group). *H*: Secreted insulin was measured with ELISA after a 15-min incubation of islets isolated from 9-week-old control (Cre) and *Htr2b* β KO mice in 2.8 or 16.8 mmol/L glucose. Insulin secretion was normalized to the total insulin content extracted from the islets ($n = 3$ /group). *I*: β -Cell mass was quantified as the percentage of insulin-positive area over whole-pancreas area of 9-week-old mice ($n = 4$ mice/group). *J*: β -Cell proliferation was quantified by counting the percentage of insulin-positive cells labeled with Ki-67 in 9-week-old mice ($n = 4$ mice/group). *K*: Pancreas weight was measured after harvest in 9-week-old mice ($n = 4$ mice/group). Scale bar = 50 μ m. Data are mean \pm SEM. * $P < 0.05$, ** $P < 0.01$ control (Cre) vs. KO; # $P < 0.05$, control (floxed) vs. KO. INS, insulin.

apoptosis and endoplasmic reticulum stress. However, we did not observe any significant difference in the TUNEL-positive cell numbers or endoplasmic reticulum stress gene expression levels in islets of *Tph1* β KO mice, and mature β -cell markers were appropriately expressed (Supplementary Fig. 3C–F). These data indicate that the reduced β -cell mass seen in adult *Tph1* β KO mice can be attributed to the reduction in perinatal β -cell proliferation. Thus, 5-HT stimulation of perinatal β -cell

proliferation is necessary to achieve the adult β -cell mass needed to accomplish normoglycemia.

5-HT Signaling Through HTR2B Regulates β -Cell Proliferation

Among the 14 HTRs in rodents, 6 are expressed in pancreatic islets (6). To determine the downstream HTRs involved in perinatal β -cell proliferation, we examined the expression levels of these 6 (HTR1B, 1D, 2A, 2B, 3A, and

3B) in embryonic pancreas. The expression levels of *Htr1b*, *Htr2b*, and *Htr3a* mRNAs showed increasing trends during pancreatic development (Fig. 3A). Among them, HTR3 is known to be involved in insulin secretion but not in β -cell proliferation (7), and the loss of HTR1B or HTR1D did not decrease β -cell proliferation at P0 (Supplementary Fig. 4). In contrast, the β -cell mass was reduced by $\sim 55\%$ in *Htr2b* β KO mice at P0, while the weight of the pancreas remained unchanged (Fig. 3B–D). The β -cell proliferation was reduced in *Htr2b* β KO mice without any obvious increase in β -cell death (Fig. 3E and Supplementary Fig. 2G). Thus, reduced perinatal β -cell proliferation was responsible for the reduction of β -cell mass in *Htr2b* β KO mice during the perinatal period.

We further analyzed the adult phenotypes of *Htr2b* β KO mice. *Htr2b* β KO mice became glucose intolerant in adulthood while exhibiting normal body weight and insulin sensitivity (Fig. 3F and Supplementary Fig. 5A and B). Plasma insulin levels at fasting and 15 min after glucose administration were lower in *Htr2b* β KO mice (Fig. 3G). However, GSIS from isolated *Htr2b* β KO islets was not significantly impaired (Fig. 3H). Instead, the β -cell mass was persistently reduced in adult *Htr2b* β KO mice to $\sim 40\%$ of control mice (Fig. 3I). The β -cell proliferation and pancreas size were similar between control and *Htr2b* β KO mice, and β -cell markers were appropriately expressed in *Htr2b* β KO mice (Fig. 3J and K and Supplementary Fig. 5C). Thus, *Htr2b* β KO mice phenocopied *Tph1* β KO mice except for the ex vivo GSIS. These data support the conclusion that 5-HT stimulates β -cell proliferation through HTR2B during the perinatal period. Furthermore, defects in 5-HT-dependent perinatal β -cell proliferation are associated with decreases in the adult β -cell mass, indicating that 5-HT plays an important role in determining the adult β -cell mass.

5-HT Is Not Involved in HFD-Induced β -Cell Proliferation

HFD is known to induce β -cell proliferation to compensate for the increased insulin demand. To further assess whether 5-HT is necessary for the ability of β -cells to

endure metabolic stress, we fed mice an HFD for 8 weeks beginning at 12 weeks of age. Neither *Tph1* expression nor 5-HT production was induced in β -cells by HFD (21) (Supplementary Fig. 6A). *Tph1* β KO mice showed a similar body weight gain and insulin sensitivity compared with control mice (Supplementary Fig. 6B and C). However, glucose intolerance was more rapidly aggravated upon HFD in *Tph1* β KO mice compared with control mice, whereas β -cell proliferation was comparable (Fig. 4A and B). These data suggest that 5-HT is not involved in the induction of compensatory β -cell proliferation in response to metabolic stress. This conclusion was further supported by measuring β -cell proliferation in mice with insulin resistance induced by the insulin receptor antagonist S-961. Induction of β -cell proliferation was comparable between control and *Tph1* β KO mice upon S-961 administration (Fig. 4C and Supplementary Fig. 6D). Thus, 5-HT stimulates β -cell proliferation not in response to metabolic stress but, rather, in response to physiological stimuli during the perinatal period. This notion prompted us to explore the upstream signals that regulate 5-HT production in β -cells during the perinatal period.

GH Induces 5-HT Production in β -Cells During the Perinatal Period

During pregnancy, placental lactogen stimulates *Tph1* expression through the PRL receptor (PRLR)-STAT5 pathway (6,22), and plasma PRL levels remain high during the perinatal period (23). To determine whether PRL induces *Tph1* expression in perinatal β -cells through the PRLR-STAT5 pathway, we investigated β -cell-specific *Prlr* KO (*Prlr* β KO) and *Stat5* KO (*Stat5* β KO) mice. Similar to observations made during pregnancy, 5-HT was not detectable in the β -cells of *Stat5* β KO mice, but in contrast to pregnancy, the β -cells in *Prlr* β KO mice still produced 5-HT at P0 (Fig. 5A). These findings suggest that different upstream signals induce *Tph1* expression during the perinatal period.

Similar to PRL signaling through PRLR, GH has been shown to act through the GH receptor (GHR) on β -cells to stimulate STAT5 phosphorylation and β -cell proliferation




Figure 4—5-HT is not involved in β -cell proliferation induced by metabolic stress. HFD was fed to 12-week-old mice for 8 weeks. **A**: Blood glucose levels were measured after intraperitoneal glucose injection (2 g/kg) after a 16-h fast ($n = 4$ –5 mice/group). **B**: β -Cell proliferation was quantified by counting the percentage of insulin-positive cells labeled with Ki-67 ($n = 4$ mice/group). **C**: β -Cell proliferation upon S-961 administration (100 nmol/kg mouse twice a day) for 7 days was quantified by counting the percentage of insulin-positive cells labeled with Ki-67 ($n = 4$ mice/group). Data are mean \pm SEM. * $P < 0.05$, ** $P < 0.01$.

(16,24). Disruption of *Ghr* in β -cells results in a decrease in the β -cell mass and insulin secretory function upon HFD (16). *GHR* expression is increased in human fetal β -cells, whereas *PRLR* expression is not (Supplementary Table 2). Therefore, we generated β -cell-specific *Ghr* KO (*Ghr* β KO) mice and found that they failed to produce 5-HT in β -cells at P0 (Fig. 5A). Consistently, *Tph1* mRNA expression was decreased in pancreas at P0 in both *Stat5* β KO mice and *Ghr* β KO mice but not in *Prlr* β KO mice (Supplementary Fig. 6E–G). The loss of 5-HT production was associated with a reduction in β -cell proliferation in both *Ghr* β KO

mice and *Stat5* β KO mice but not in *Prlr* β KO mice (Fig. 5B–E). Consistent with these reductions in β -cell proliferation, the β -cell mass was reduced in *Ghr* β KO mice and *Stat5* β KO mice but not in *Prlr* β KO mice (Fig. 5F–H).

Next, we examined whether GH can directly induce 5-HT production in β -cells during the perinatal period. Plasma GH levels peaked at embryonic day 17.5 (E17.5) and gradually declined after birth (Supplementary Fig. 6H). GH treatment directly increased the expression of *Tph1* and *Mki67* in wild-type islets, and this response was perturbed in *Tph1* β KO islets (Fig. 5I and J). GH also




Figure 5—GH regulates 5-HT production in β -cells during the perinatal period. Pancreas of control (Cre), *Prlr* β KO, *Stat5* β KO, and *Ghr* β KO mice at P0 were examined. **A**: 5-HT production in β -cells at P0 were assessed by immunofluorescent (IF) staining, which labeled 5-HT (red) and insulin (green). **B**: Representative H&E staining and IF staining, labeled insulin (green) and phospho-Histone H3 (PHH3) (red) at P0. Arrows indicate insulin and PHH3 copositive cells. **C–E**: β -Cell proliferation of *Prlr* β KO, *Stat5* β KO, and *Ghr* β KO mice at P0 was quantified by counting the percentage of insulin-positive cells labeled with PHH3 ($n = 4–6$ mice/group). **F–H**: β -Cell mass was quantified as the percentage of insulin-positive area over whole-pancreas area in *Prlr* β KO, *Stat5* β KO, and *Ghr* β KO mice at P0 ($n = 4–6$ mice/group). **I** and **J**: Induction of *Tph1* or *Mki67* in islets isolated from 3-week-old control (Cre) and *Tph1* β KO mice was measured by qRT-PCR. Islets were incubated with recombinant mouse GH (1,000 ng/mL) for 24 h ($n = 3–5$ /group). **K**: Schematic describing the GHR-STAT5-TPH1-HTR2B axis for β -cell proliferation during the perinatal period. Scale bars = 50 μ m. Data are mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. INS, insulin.

increased *Tph1* expression in β TC3 and MIN6 cells (Supplementary Fig. 6I). However, no significant difference in HTR expression was observed upon GH treatment (Supplementary Fig. 6J). These results suggest that GH signals through GHR-STAT5 to stimulate TPH1 expression during the perinatal period, which in turn induces 5-HT production in β -cells.

Taken together, we identified that 5-HT plays a key role in determining the adult β -cell mass by regulating β -cell proliferation during the perinatal period (Fig. 5K). GH binds to GHR and activates STAT5 to stimulate 5-HT production by increasing TPH1 expression in perinatal β -cells. In turn, 5-HT stimulates β -cell proliferation through HTR2B in an autocrine/paracrine manner. Remarkably, defects in this pathway lead to a reduction in adult β -cell mass and glucose intolerance, which is exacerbated by metabolic stress.

DISCUSSION

Pancreatic β -cells undergo physiological mass expansion during the perinatal period and pregnancy. Intriguingly, 5-HT production increases robustly in β -cells during both periods, and 5-HT/HTR2B works as a common mechanism for β -cell proliferation in response to different external upstream signals (6,8). 5-HT production in human β -cells has also been reported by multiple groups (6,25–27), although this has been argued, as the expression of *TPH1* is low and STAT5 functions differently in human β -cells (28,29). Recent advances in β -cell transcriptomics support our hypotheses that 5-HT is produced from perinatal β -cells to stimulate its proliferation through HTR2B (Supplementary Table 2). Blodgett et al. (20) performed RNA sequencing analysis of sorted human β -cells, which showed that *TPH1* expression was enriched in fetal β -cells compared with adult β -cells, and *GHR* expression was 10-fold higher in fetal β -cells. *HTR2B* was among the most abundant HTR transcripts in human fetal β -cells, although potential contributions by other HTRs should be further investigated. Qiu et al. (30) performed transcriptomic analysis of mouse β -cells sorted from different perinatal periods and found that *Tph1* expression peaks at P0, which is in accordance with our findings. We also directly demonstrated the presence of 5-HT in fetal and perinatal human β -cells.

GH production increases during fetal development and surges at birth (10–50 ng/mL) (31,32). After birth, the GH level falls within 1 month to <10 ng/mL (32,33). Transient and robust 5-HT production in β -cells during the perinatal period parallels these dynamic changes in GH levels in both humans and mice. Our results showing defects in β -cell proliferation in each β KO model of the GHR-STAT5-TPH1-HTR2B axis are in accordance with previous reports showing that β -cell proliferation and cyclin D2 expression are altered in models of reduced GH signaling (34–37). In humans, children requiring GH replacement have a six- to eightfold higher incidence of diabetes relative to age-matched untreated children

(38,39). Inadequate GH stimulation at an earlier age in these children may increase the risk of diabetes by reducing the perinatal expansion of the β -cell mass. In addition, the yield of islet clusters increases when human fetal pancreas are cocultured with GH (40). These data support the potential implication of GH in the expansion of the β -cell mass.

In summary, we show that 5-HT plays a critical role in GH signaling to determine the β -cell mass by regulating β -cell proliferation through HTR2B during the perinatal period. Future studies of this pathway may provide new insights into the genetics and pathophysiology of diabetes and could suggest new methods for regenerating β -cells for people with diabetes.

Acknowledgments. The authors thank Hee-Saeng Jung, Ju Eun Kim, and Hannah Jung (Korea Advanced Institute of Science and Technology) for technical support; Drs. Gerold Grodsky and William Rutter (University of California, San Francisco) for helpful discussions; Dr. Gerard Karsenty (Columbia University) for the *Htr2b* floxed mice; Dr. Lothar Hennighausen (National Institute of Diabetes and Digestive and Kidney Diseases) for the *Stat5* floxed mice; Do Yon Kim and Dr. Yong-Sam Kim (Korea Research Institute of Bioscience & Biotechnology) for help with GHR studies; Dr. Lauge Schaffer (Novo Nordisk) for S-961; and all of laboratory members for helpful discussions.

Funding. This work was supported by grants from the Health Fellowship Foundation (to J.H.M.), National Research Foundation of Korea (grant numbers NRF-2017H1A2A1042095 to J.H.M., NRF-2014H1A8A1022054 to Y.G.K., NRF-2013H1A8A1003985 and NRF-2018R1A6A3A01012333 to Hy.K., and NRF-2015M3A9B3028218 and NRF-2018R1A2A3074646 to Ha.K.), National Institutes of Health (P30-DK-063720 to M.S.G.), Larry L. Hillblom Foundation (2014-D-004-NET and 2018-D-006-NET to M.S.G.), and JDRF (10-2010-553 to Ha.K.). Some of this research was performed using resources and/or funding provided by the National Institute of Diabetes and Digestive and Kidney Diseases–supported HIRN (RRID:SCR_014393; <https://hirnetwork.org>; UC4 DK104211, DK108120), by grant numbers DK106755 and DK20593, and by grants from The Leona M. and Harry B. Helmsley Charitable Trust and the Department of Veterans Affairs (BX000666) to A.C.P.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. J.H.M., Y.G.K., K.K., S.W., J.W., K.Y., Hy.K., J.L., J.-S.J., and Y.W. performed the animal experiments and analyzed the obtained data. S.O., D.C.S., H.M., and A.C.P. performed the human experiments and analyzed the obtained data. J.H.M., Y.G.K., R.R.B., S.K.K., Y.W., H.M., A.C.P., M.S.G., and Ha.K. analyzed the data and reviewed the manuscript. J.H.M., Y.G.K., M.S.G., and Ha.K. generated the hypothesis, designed the experiments, and wrote the manuscript. Ha.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. *J Clin Invest* 2006;116:1802–1812
2. Kendall DM, Sutherland DE, Najarian JS, Goetz FC, Robertson RP. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. *N Engl J Med* 1990;322:898–903
3. Gregg BE, Moore PC, Demozay D, et al. Formation of a human β -cell population within pancreatic islets is set early in life. *J Clin Endocrinol Metab* 2012;97:3197–3206
4. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. *Science* 2003;299:76

5. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. Tryptophan hydroxylase-2 controls brain serotonin synthesis. *Science* 2004;305:217
6. Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. *Nat Med* 2010;16:804–808
7. Ohara-Imaizumi M, Kim H, Yoshida M, et al. Serotonin regulates glucose-stimulated insulin secretion from pancreatic β cells during pregnancy. *Proc Natl Acad Sci U S A* 2013;110:19420–19425
8. Ohta Y, Kosaka Y, Kishimoto N, et al. Convergence of the insulin and serotonin programs in the pancreatic β -cell. *Diabetes* 2011;60:3208–3216
9. Herrera PL, Orci L, Vassalli JD. Two transgenic approaches to define the cell lineages in endocrine pancreas development. *Mol Cell Endocrinol* 1998;140:45–50
10. Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. *Development* 2000;127:2317–2322
11. Cui Y, Riedlinger G, Miyoshi K, et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. *Mol Cell Biol* 2004;24:8037–8047
12. Kim H, Kim YG, Choi W, et al. Generation of a highly efficient and tissue-specific tryptophan hydroxylase 1 knockout mouse model. *Sci Rep* 2018;8:17642
13. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. *Cell* 2008;135:825–837
14. Banerjee RR, Cyphert HA, Walker EM, et al. Gestational diabetes mellitus from inactivation of prolactin receptor and MafB in islet β -cells. *Diabetes* 2016;65:2331–2341
15. Li L, Gao L, Wang K, et al. Knockin of Cre gene at Ins2 locus reveals no Cre activity in mouse hypothalamic neurons. *Sci Rep* 2016;6:20438
16. Wu Y, Liu C, Sun H, et al. Growth hormone receptor regulates β cell hyperplasia and glucose-stimulated insulin secretion in obese mice. *J Clin Invest* 2011;121:2422–2426
17. Brouwers B, de Faudeur G, Osipovich AB, et al. Impaired islet function in commonly used transgenic mouse lines due to human growth hormone minigene expression. *Cell Metab* 2014;20:979–990
18. Kim H, Kim H, Kim K, German MS, Kim H. Ectopic serotonin production in β -cell specific transgenic mice. *Biochem Biophys Res Commun* 2018;495:1986–1991
19. Szot GL, Koudria P, Bluestone JA. Murine pancreatic islet isolation. *J Vis Exp* 2007;(7):255
20. Blodgett DM, Nowosielska A, Afik S, et al. Novel observations from next-generation RNA sequencing of highly purified human adult and fetal islet cell subsets. *Diabetes* 2015;64:3172–3181
21. Kim K, Oh CM, Ohara-Imaizumi M, et al. Functional role of serotonin in insulin secretion in a diet-induced insulin-resistant state. *Endocrinology* 2015;156:444–452
22. Schraenen A, Lemaire K, de Faudeur G, et al. Placental lactogens induce serotonin biosynthesis in a subset of mouse beta cells during pregnancy. *Diabetologia* 2010;53:2589–2599
23. Freemark M. Ontogenesis of prolactin receptors in the human fetus: roles in fetal development. *Biochem Soc Trans* 2001;29:38–41
24. Höglund E, Mattsson G, Tyrberg B, Andersson A, Carlsson C. Growth hormone increases beta-cell proliferation in transplanted human and fetal rat islets. *JOP* 2009;10:242–248
25. Bennet H, Balhuizen A, Medina A, et al. Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes. *Peptides* 2015;71:113–120
26. Almaça J, Molina J, Menegaz D, et al. Human beta cells produce and release serotonin to inhibit glucagon secretion from alpha cells. *Cell Rep* 2016;17:3281–3291
27. Kim YG, Moon JH, Kim K, et al. β -cell serotonin production is associated with female sex, old age, and diabetes-free condition. *Biochem Biophys Res Commun* 2017;493:1197–1203
28. Goyvaerts L, Schraenen A, Schuit F. Serotonin competence of mouse beta cells during pregnancy. *Diabetologia* 2016;59:1356–1363
29. Chen H, Kleinberger JW, Takane KK, et al. Augmented Stat5 signaling bypasses multiple impediments to lactogen-mediated proliferation in human β -cells. *Diabetes* 2015;64:3784–3797
30. Qiu WL, Zhang YW, Feng Y, Li LC, Yang L, Xu CR. Deciphering pancreatic islet β cell and α cell maturation pathways and characteristic features at the single-cell level. *Cell Metab* 2018;27:702
31. Kaplan SL, Grumbach MM, Shepard TH. The ontogenesis of human fetal hormones. I. Growth hormone and insulin. *J Clin Invest* 1972;51:3080–3093
32. Hawkes CP, Grimberg A. Measuring growth hormone and insulin-like growth factor-I in infants: what is normal? *Pediatr Endocrinol Rev* 2013;11:126–146
33. Zadik Z, Chalew SA, McCarter RJ Jr., Meistas M, Kowarski AA. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. *J Clin Endocrinol Metab* 1985;60:513–516
34. Galsgaard ED, Friedrichsen BN, Nielsen JH, Møldrup A. Expression of dominant-negative STAT5 inhibits growth hormone- and prolactin-induced proliferation of insulin-producing cells. *Diabetes* 2001;50(Suppl. 1):S40–S41
35. Jackerott M, Møldrup A, Thams P, et al. STAT5 activity in pancreatic beta-cells influences the severity of diabetes in animal models of type 1 and 2 diabetes. *Diabetes* 2006;55:2705–2712
36. Friedrichsen BN, Richter HE, Hansen JA, et al. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. *Mol Endocrinol* 2003;17:945–958
37. Liu JL, Coschigano KT, Robertson K, et al. Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. *Am J Physiol Endocrinol Metab* 2004;287:E405–E413
38. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. *Lancet* 2000;355:610–613
39. Child CJ, Zimmermann AG, Scott RS, Cutler GB Jr., Battelino T, Blum WF; GeNeSIS International Advisory Board. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program [published correction appears in *J Clin Endocrinol Metab* 2011;96:2624]. *J Clin Endocrinol Metab* 2011;96:E1025–E1034
40. Sandler S, Andersson A, Korsgren O, et al. Tissue culture of human fetal pancreas: growth hormone stimulates the formation and insulin production of islet-like cell clusters. *J Clin Endocrinol Metab* 1987;65:1154–1158